KAER Biotherapeutics ™ has developed a new class of aerosol delivery system for the treatment of respiratory and other diseases. This technology excels where the delivery of large masses of labile agents are required to be delivered to the respiratory tract. KAER™ brings added value to pharmaceutical and biotechnology companies by the delivery of their drug with SUPRAER™ technology.   For those diseases that require doses of 10 to 100 mg of medication in the clinic or at home SUPRAER™ has a clear competitive advantage.   

KAER adds value to your biologic

Biologics comprise 45% of the drug development pipeline.   Some of these are administered intraveneously . Aerosol delivery via the respiratory tract is the preferred mode of administration for many of these, including :- proteins, surfactants, oligonucleotides , antibodies, and liposomes .   High doses of anticancer agents and antibiotics are also required to be deposited in the lungs.

Whereas there is a good choice of nebulizers to deliver micrograms of small molecules, the delivery of tens of milligrams of biotherapeutics presents formidable barriers not adequately addressed by present liquid or dry powder aerosol delivery systems. These include:-

•  Inability to nebulize large macromolecules

•  Shear-induced molecular degradation

•  Difficult formulation

•  Unwanted excipients

•  Long delivery times

SUPRAER™ by KAER is a patent-pending new class of aerosol delivery system which overcomes all of these issues.

The major challenges in aerosol drug delivery are proper nebulizer use and compliance. SUPRAER™ provides both drug dosimetry and respiratory indicators.   SUPRAER™ delivers aerosols of large molecules without degradation at a rate of 2mg/sec with no system-imposed limit on the time and volume of inhalation.    Thus, for instance, a protein aerosol therapy which takes 20 min to 1 hour with present nebulizers is achieved in just a few minutes with SUPRAER™.   Clearly the shorter inhalation times address both of these issues as well as being highly desirable by the patient.   Collectively, these directly lead to improved efficacy.

Pharmaceutical companies whose biologics pipeline is targeted at those disease entities which can be treated on a chronic basis have limited choices for aerosol delivery systems.   Market entry is accelerated by selection of an orphan drug/device combination facilitated by SUPRAER's marked improvement in aerosol drug delivery.

As SUPRAER™ does not require the use of excipients considerable savings in formulation and safety pharmacology costs are realized.   In addition, there is a reduced time-to-market.  

The use of SUPRAER™ provides compelling revenue generation for the pharmaceutical company as well as for KAER™.